Partner with leaders on the ground to meet people where they are with vaccines, tests, treatments and information. Over the last couple of weeks, our large event pilot has been incredibly successful. Over 3300 shots were administered in new orleans. Over 1,000 shots were administered at oakland pride and over 4,000 shots were administered at black friday in atlanta. And we recently were notified that charlotte administrated another 1500 doses in the days and events following charlotte pride last month. With the total vaccine doses to nearly 11,000. These efforts are reaching black and brown communities, a top priority of this administration. By vaccining thousands of people at highrisk who might not otherwise have gotten a shot, this program is working to advance equity and combat this outbreak. We continue to build on this work by making additional Vaccines Available for large and small equity interventions across the country. Which the doctor will talk about more. Stepping back, were seeing the impact of thissed a of the administrations comprehensive strategy to fight monkeypox and the latest case trends and other promising data points. Overall, new case numbers are down nearly 50 since early august. And in places like atlanta where weve worked closely with the Public Health community to surge vaccines and information around events like black pride, the rate of new cases has steadily declined. And in d. C. The new cases have declined 20 on average per week since a peak in mid july. And knowledge of our tools and interests in using them has increased. According to Research Released today from the university of pennsylvania, knowledge of a Monkeypox Vaccine has jumped from approximately 1 3 of americans to over 60 . More than 2 3 of americans understand the risk profile and behaviors from monkeypox. And nearly 3 4 of americans said they would get vaccinated if exposed to monkeypox. What this shows us is that our work to expand knowledge of monkeypox and our tools to fight it, alongside so many local Health Departments and other Community Organizations is working. We know theres a lot more to do, especially for black and brown communities where the burden remains high. But theres no question that the work weve done directly increased vaccine supply, get people vaccinated, wrap up the availability ramp up the availability of testing and treatments and educate individuals on how they can protect themselves is making a tremendous difference. The adminute administrations strategy the administrations strategies is working. As youll hear, well continue to work nonstop to get more shots in arms, more information out to the highest risk individuals and learn as much as we can about this virus and our treatments so we can quickly and effectively end this outbreak. With that, let me turn to dr. Fauci who will talk about Clinical Trials recently launched to make sure we can effectively treat those who have contracted the virus. Dr. Fauci talking to you about what bob mentioned but also giving somewhat of a brief overview, if i can have the first slide, of the n. I. A. And the Research Priorities for monkeypox which generally and broadly all under five major killers. There are a number of unanswered questions, so as we implement the interventions that we have, simultaneously well pursue some unanswered questions. Namely, addressing gaps in basic virology and immunology and immune correlates. Understanding better transmission, as well as the issue of animal reservoirs not only potentially here in the United States but also globally. Also the importance of developing new diagnostics and assays, particularly diagnostics to be able to determine if we can see if a person in the asymptomatic or presymptomatic stage, that doesnt have an obvious lesion, if theres some diagnostic test we can do to alert to us that and therefore help stop the spread. Also to evaluate new treatments, im going to speak about one of the treatments that we have and how were improving our knowledge of that, but also the development of other antiviral drugs. And then finally and importantly, to optimize and advance our vaccine regiments. Next slide. What im going to mention in the next couple of minutes are two significant Clinical Trials. One in the therapeutics. There were two trials within that category. One here in the United States and one internationally. And then also to take a look at the vaccine studies that were doing. If i can have the next slide. In the United States we are conducting, and it has already started on september 8, a phase iii trial of tecovirimat for monkeypox in the United States. Thats referred to as the stomp trial. Standing for the study of tecovirimat for human monkeypox virus. As you know, the tpoxx is approved for smallpox by the animal rule, but for monkeypox, it still is under an expanded access. So the plan will include 60 clinical sites in the United States with a target enrollment of 530 people. Were going to randomize people two to one to receive tpoxx versus placebo. A very important aspect of this that we learned from our experience back in the days of h. I. V. Is to get the Community Involved in being able to determine what is best for in tn segment and enroll children such as breastfeeding individuals and others with severe disease. If a person comes in and has severity of disease, they can be in the trial, but in an openlabel component and will receive tpoxx. And more information about this trial is shown on the slide. Next slide. In addition to that, we are doing the trial of the drug for monkeypox in the congo. Recall when you look at the different claims, the congress of claim is one which has a higher degree of mortality compared to the very low agree of mortality in the clay 2s that are currently in the United States. This trial again is a placebocontrolled trial that will open its code red by the niaid. And again, the target is 450 adults and children in weight three kilograms or more with Laboratory Confirmed infection. Pregnant women are eligible and in the d. R. C. And that study the participants will be randomized and to tpoxx or placebo. The target is 200 individuals from 1850 across eight United States sites. Now the participants are going to be signed at random to one of three studies. Either the study administered but they will be two separate doses, 15 of the standard dose that was the one authorized by the f. D. A. And 110 standard dose. The 110 is to determine because in the United States, we have enough doses to handle the people who are at risk. But this is a global and make a contribution that 110 works that will immediately double the amount of doses double on an International Scale and determine whether the peak responses induced are at least as good as the responses introduced with regard to the license regimen. As of september 14, 59, 600 cases have been detected. In the United States there have been 23 cases of monkey pox identified across all 50 states and district of puerto rico. We have been pleased to see a decline in the growth of new cases here and abroad. Owe there are areas of the u. S. Where the rise of new cases is still and we view it with carbous optimism. And the work being done and people who have made informed decisions to make temporary changes to their behavior to protect themselves and we must continue to aggressively respond with our entire tool kit. Over the several kits we have seen the makeup of this evolve. While they were first seen in Nonhispanic White men, in the last week the cases for which we have data, nonhispanic black men represented 38 . Latino represented 25 of cases and Nonhispanic White men represented 26 of cases. We continue to monitor data, those at risk and how prevention measures are being yesterday. We continue to work closely with jurisdictions to make their data available. To date, over 540,000 doses of vaccine have been administered over the and increase in second doses administered as more people have become eligible and 28 days after the first dose. As a reminder, and it is important to receive the second dose to have the best occurred 14 days after that second dose. Working closely with jurisdictions to provide the most complete picture, we have been able to receive data for over 91 of the first doses reported. And those who are white represent about 47 of people and hispanic represent 21 and those for blacks represent 12 . Given the data that i showed earlier, the percentage of vaccines administered to latinos and are disproportionately lower than we are seeing in cases. It is critical that education, vaccinations, testing and treatment are accessible to all populations but those most affected by the most to reduce ethnic disparities and overcome barriers, u. S. Government launched two Pilot Programs to provide vaccines, which the doctor will outline in more detail. We have had success with this approach with the at large gatheringings. This will engage with communities in smaller events and interventions focused on addressing disparities. The program is open and available on c. D. C. s website and we will discuss this in further detail. We continue to Prioritize Health equity in all of the work we do and i am proud of the work to the opportunity for equity it represents. I will now turn it over. As we said, equity must remain the cornerstone of our response and currently some jurisdictions are seeing increasing rates of infections and monkeypox cases engaged bisexual and men who have sex with men of color. Earlier doctors as we see in the data have begun or completed their vaccination series and entering the harder phase. We need to make sure we continue to get first doses into arms and ease access. We need to use hyper local strategies and reach deeper into the community. We launched focusing have resulted in 11,000 doses getting into the arms of people who might not have sought services. 63 of vaccines have gone into arms. In georgia, nearly 70 of the people who were vaccinated at black pride identify as nonwhite and 70 of the vaccines were to black people. These interventions are working and we have more coming. These largescale events are one lever but we know outreach will make the difference. Thats why today we are Opening Applications for our second equity intervention pilot that focuses on smaller projects to link the Monkeypox Vaccines, education and treatment. Health departments will use local experience and connection to the community to identify strategies to improve Vaccine Access to communities of color to those who are overrepresented. C. D. C. Will provide them with vaccines, materials and the assistance needed to realize these local interventions and help us learn what is needed to populations. We have allocated 10,000 vials for these smaller equity interventions and the application is going to be available on the website and the administration will be promoting this new Pilot Program to help Community Partners as well as through social media. Monkeypox is not an infection. It travels with h. I. V. And last week, c. D. C. Communicated to these funded Health Department and h. I. V. Based Community Organizations their their staff and dollars could be used to use and same people we need to are the same people who need Services Like testing, education and vaccines. And allows our frontline Health Departments and communitybased organization to use their resources to accelerate all to the end of the monkeypox outbreak and prevention for the exact same population. This is just the latest example of us being responsive to what is happening on the ground and pivoting our focus and resources where they are most needed. Thank you. Thanks, doctors. Kevin, lets open it up for questions. Lets go to ahmed. Thanks for taking my question. For dr. Walensky. What do you attribute. [indiscernible] how considerate of confident we arent go to go see a rebound. And going why the population [indiscernible] first, we should note that we have made strong progress and we are encouraged by cases and the case rates are declining and keeping the gas pedal, pedal to the metal as we continue our and what do i attribute it to . The multi layered approach. The testing and the massive and the vaccinations we have been able to get out and we are working to get harder to reach communities and communities that might not have been first in line and thats where we are with all of these activities. This is a tool kit. The behavior change, the vaccine, the testing and messaging and equity focus are going to lead us to control of this outbreak. And i address the question about spread to other populations we have vigilance and dr. Walensky can speak to that. What we are seeing is terminal change in those populations. It is not efficient groups which this is transmitting. So awareness is what matters. Sorry to interrupt. We have done extraordinary outreach to providers in that and calls with k12 educators and Health Educators to make sure they know what they are looking for should a patient come in. And we have seen terminal change if and should there be a single case we dont see extension of those cases in those settings. Kevin, another question. You are focusing on equity and what you are doing to ensure there is no come placensy and drive these cases down . This is bob. Its all the tools and we ensure that the update continues to improve and work to vaccinate those with the hardest to reach and bring vaccines. Let me turn to dr. Walensky first to speak in more detail about some of those efforts. A lot of that in addition to providing those vaccines is the vaccines and resources and education and folks on the ground teaching people in the community and how they can protect themselves and what can lead to more infection and change their behavior and more we do that, the more that knowledge increases and when we have that knowledge increase, we see that communities understand and understand how to protect themselves and understand the behaviors that increase risk and understand how vaccination could decrease risk and it is outreach to providers and for the community. What is exciting the Administration Strategy here is working. Dr. Walensky and mr. Fienton have been clear its about education and testing and treatment and about vaccine. You dont use one tool in the tool kit to build a house but use all of the tools and we are using all of them together and we have positive tools from the university of pennsylvania that our messaging is coming through and what we are actually seeing numbers in the outbreak. We have the hard part of the job to do. The earlier doctors have listened and honker down and the jurisdictions are doing on their own. One other thing i think is important, we talk about the lessons that we have learned from h. I. V. That are positive lessons, back in the day we were seeing patients in the 1980s and telling physicians to ask questions of patients that they would not have asked before, sexual activity, which the diagnostics are right up there. As dr. Walensky, when you go out to the providers and tell them to be alert to things they may not have otherwise looked for, that was the way to answer the question that was just asked, how do you know to pick up things in the community that you didnt see before. It is an important lesson we learned from h. I. V. We are not the only ones that have our foot on the gas pedal. The community has their foot on the gas pedal and helping us to address the outbreak and the research that we need so we understand how to use tpoxx and vaccines. So it is an all of society effort and kudos for putting their foot on the pedal. Kevin, another question. Chris johnson. Thanks for taking this call. You talk about the call on one hand, equity has been a primary focus in the monkeypox outbreak and seeing numbers where new cases are shifting increasing among men of color. Why do you think these efforts of increased efforts for equity are not having an effect of boost boosting equity. Let me start with dr. What lense. And it is before we even saw those shifts, we embarked on these activities because we anticipated this might be happening and exactly for these reasons we started on these pilot projects before we saw shifts in data and often the case that we have vulnerable population who are most impacted later on. While we anticipated, we have embarked on these activities to address this in exactly this moment. I have spoken to providers on the ground and promoters of these events who have noted that this effort is unprecedented in reaching deeply into these communities and i think as dr. Walensky said all of our commitment in the administration is to focus efforts on equities to resolve the issues we are seeing. It is a hard effort and a challenge and the way to address is intention. See if we get another country . One from n. P. R. Thanks for taking my question. Dr. Fauci [indiscernible] dr. Fauci two parts to your question, when you talk about the other basic questions that i asked, they are not yet at the level of Clinical Trial. What we will be doing is developing the tools that will get translated into a Clinical Trial. For example, when you are talking about immunology. In the tea pot study, we will be looking for resistance to tpoxx and immune corollaries. The Clinical Trials are the ones ongoing. And preclinical to advanced development. We are still at the level when you screen for new drugs, you develop vaccines looking at the cycle of the virus which for us we have decades of virus and utilize to use molecules that are existing to develop them or development of brand new molecules aimed at that. With